Century Sage Scientific (1450) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Century Sage Scientific HK$2.17, price HK$0.61, upside +258.7%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Century Sage Scientific for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range HK$0.1377 – HK$4.03 · fair‑value band HK$1.52 – HK$2.82 · the HK$0.6050 price screens below the HK$2.17 fair value. Dashed = 300-day average. As of Sep 28, 2026.
Follow Century Sage Scientific in your weekly email
Every Wednesday you see whether Century Sage Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Be Friends Holding Limited, an investment holding company, provides all-media services in the People's Republic of China.
Show more
Be Friends Holding Limited, an investment holding company, provides all-media services in the People's Republic of China. The company offers new media services, such as marketing services to the merchants for the livestream e-commerce on the e-commerce platforms; and application solutions, including design, implementation, and support services, as well as offers broadcasting equipment. It also sells self-developed equipment and related products; and provides system maintenance services comprising maintenance, training, and other supporting services. The company serves media platforms, industrial customers, and broadcasters. The company was formerly known as Century Sage Scientific Holdings Limited and changed its name to Be Friends Holding Limited in July 2023. Be Friends Holding Limited was founded in 2007 and is headquartered in Hangzhou, the People's Republic of China.
Stock analysis
Century Sage Scientific (1450) currently trades at HK$0.6050, while our model-based Fair Value estimate is HK$2.17, implying the stock looks roughly 72.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$3.69 per share, and 22 of the 24 models we run sit above the HK$0.6050 price.
Bear case: the Asset-Based group reads lowest at HK$0.3000, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$1.52 (bear) to HK$2.82 (bull), the price of HK$0.6050 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Technology sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Century Sage Scientific reported revenue of 1.5B CNY in FY2025 versus 203M CNY in FY2021, a compound +64.5%/yr. Reported net income was 90.2M CNY in FY2025.
Key figures
Market cap HK$1.0B (≈ $131M) · P/E ratio 9.3 · P/S ratio 0.56 · EPS (TTM) HK$0.0400 · Dividend yield 7.4% · Net margin 6.1% · Return on equity 19.0% · Return on assets (EBIT) 6.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −8% fair-value upside, at 259%, 1450 screens cheaper than that median.
Fair Value models
Bear HK$1.52Fair Value HK$2.17Bull HK$2.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.5%
Start year 2020 (pandemic). Over 10 years: +9.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−1.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.2%
Dividend (yield on the price)7.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−45% → 9%
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Compare Century Sage Scientific with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 636 stocks
Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)19.0% · Top 25%
Return on assets8.6% · Top 25%
Net margin (TTM)6.1% · Above median
Operating margin (TTM)6.7% · Above median
Growth and dividend
Revenue growth38.1% · Top 25%
Dividend yield (TTM)7.4% · Top 25%
Valuation Multiplesvs Software - Application median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Century Sage Scientific (1450) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of HK$2.17 versus a price of HK$0.6050, about +259% upside (undervalued).
What is the fair value of 1450?
Our model-based fair value for Century Sage Scientific is HK$2.17 (as of Sep 28, 2026), built from audited fundamentals. The current price: HK$0.6050.
What is the quality score of 1450?
Century Sage Scientific has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Century Sage Scientific (1450)?
Our model-based price target is the fair value of HK$2.17 (as of Sep 28, 2026) from 24 valuation models. Cautious scenario HK$1.52, optimistic scenario HK$2.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Century Sage Scientific stock forecast for 2026?
Our models put fair value at HK$2.17, about +259% upside versus a price of HK$0.6050 (undervalued). Cautious scenario HK$1.52, optimistic scenario HK$2.82. The calculation is refreshed regularly with new filings.
What is the revenue of Century Sage Scientific (1450)?
Century Sage Scientific reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Sep 28, 2026).
Does Century Sage Scientific pay a dividend?
Century Sage Scientific currently shows a dividend yield of about 7.44% relative to its recent price (as of Sep 28, 2026).
What growth is priced into Century Sage Scientific (1450)?
For today's price to be fair in a discounted-cash-flow model, Century Sage Scientific would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +57.5 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of 1450 use?
Our models discount Century Sage Scientific at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Century Sage Scientific that is less than minus 40 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Century Sage Scientific (1450) delivered so far?
Over the past 5 years revenue at Century Sage Scientific grew +57.5 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Century Sage Scientific (1450) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Century Sage Scientific (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Century Sage Scientific (1450)?
The free-cash-flow yield on the price is 48.81 %: that much free cash flow Century Sage Scientific produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Century Sage Scientific (1450)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Century Sage Scientific it is HK$2.17 per share (as of Sep 28, 2026), against a price of HK$0.6050. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Century Sage Scientific stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 1450 trades below its calculated fair value: price HK$0.6050, fair value HK$2.17, a gap of about +259% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1450?
No. The price is what the market pays today (HK$0.6050); the fair value is what the company's own numbers justify (HK$2.17). For Century Sage Scientific the two are HK$1.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Century Sage Scientific worth?
The market values Century Sage Scientific at about HK$1.0B (market capitalisation, as of Sep 28, 2026). Per share that is HK$0.6050; our models calculate a fair value of HK$2.17 per share.
What do the bullish and bearish scenarios say about 1450?
Our models span a range for Century Sage Scientific: cautious scenario HK$1.52, base HK$2.17, optimistic HK$2.82 per share (as of Sep 28, 2026, price HK$0.6050). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1450?
Century Sage Scientific trades at a price-to-earnings ratio of 9.3 (as of Sep 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.17 is built from several models across several years. Other multiples: P/B 1.6, P/S 0.6, EV/EBITDA 3.7.
How solid is the balance sheet of Century Sage Scientific (1450)?
Balance-sheet figures for Century Sage Scientific (as of Sep 28, 2026): return on equity 19.0%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 1450 from its 52-week high?
Century Sage Scientific trades at HK$0.6050, about 47% below its 52-week high of HK$1.13 and 2% above the low of HK$0.5950 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.17 is for.
Which stocks are comparable to Century Sage Scientific?
From the same area (Technology) we also value SAP SE, Salesforce, Inc, Shopify Inc, ServiceNow, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Century Sage Scientific stock attractive at the current price?
The data as of Sep 28, 2026: price HK$0.6050, calculated fair value HK$2.17 (+259%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1450 calculated?
We run Century Sage Scientific through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Century Sage Scientific currently trades 72 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Century Sage Scientific (1450)?
The closing price on Oct 2, 2026 was HK$0.6050. Our model-based fair value is HK$2.17, about +259% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Century Sage Scientific right now?
The price is below even our cautious bear case (HK$1.52). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$1.52 to HK$2.82) leaves room in how you read the outcome.
Where does the earnings growth of Century Sage Scientific (1450) come from?
Earnings per share at Century Sage Scientific grew +0.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.0 %, EBIT margin −2.6 %, tax rate −1.4 %, residual (interest, one-offs) +1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Century Sage Scientific
How large is the market capitalisation of Century Sage Scientific (1450)?
The market capitalisation of Century Sage Scientific is HK$1.0B (≈ $131M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Century Sage Scientific (1450)?
The price-to-sales ratio of Century Sage Scientific is 0.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Century Sage Scientific (1450)?
Earnings per share at Century Sage Scientific are HK$0.0400 (price ÷ EPS = P/E 9.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Century Sage Scientific (1450)?
The dividend yield of Century Sage Scientific is 7.4% (payout 113%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Century Sage Scientific (1450)?
The net margin of Century Sage Scientific is 6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Century Sage Scientific (1450)?
The return on equity (ROE) of Century Sage Scientific is 19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Century Sage Scientific (1450)?
On an EBIT basis the return on assets of Century Sage Scientific is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Century Sage Scientific (1450)?
The operating margin of Century Sage Scientific is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Century Sage Scientific (1450)?
Revenue at Century Sage Scientific is growing +38.1% versus a year earlier (3y avg +51.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Century Sage Scientific (1450)?
Earnings per share at Century Sage Scientific are growing −30.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Century Sage Scientific (1450) hold?
Century Sage Scientific holds more cash than debt, 255M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Century Sage Scientific in the live analysis
One click puts Century Sage Scientific on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
